About this tesamorelin research terminal

What this project is

Reviews Tesamorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "reviews" in the name means a review of the evidence — a systematic readout of the published trial record — not personal testimonials, before-and-after photos, or user ratings. Every quantitative claim on the site maps to a numbered citation in the full reference list, and where the data is thin or absent, we say so in plain view rather than filling the gap.

Why it reads like a terminal

Tesamorelin has one of the most quantitative evidence bases in its compound class — a 15.2% visceral-fat reduction in the pivotal trial ^[1], -18% sustained at 52 weeks ^[2], an IGF-1 rise of 81.0% and of 181 µg/L ^[1][4], a -2.9% hepatic-fat JAMA effect ^[3], and pooled odds of 3.9 for reducing visceral fat below threshold ^[10]. A terminal-style readout suits that record: each datum is printed like a returned value, with its source and its scope beside it.

The scope discipline is the point. The measured numbers belong to the HIV-associated-lipodystrophy population; the benefit reverses on discontinuation ^[2][6]; non-HIV general fat loss is mechanistically plausible but not established by a large RCT ^[4]; FDA approval covers one indication only ^[5]; and the compound is WADA-prohibited in sport. We surface those boundaries as first-class elements, not footnotes.

How the record is compiled

The sources behind this site are the primary literature: randomized controlled trials, the JAMA and NEJM reports, the population pharmacokinetic analysis, the NIH LiverTox monograph, and the most recent meta-analysis, each listed with a DOI or PubMed identifier on the references page. When a figure appears in the body copy, it is tagged to one of those numbered entries so a reader — or a machine reading the page — can trace it to source. We prioritize the measured endpoint over the marketing claim, and we keep the off-label boundary visible rather than implied. Where the contemporary evidence is thin, as with non-HIV fat loss ^[4] or a head-to-head against sermorelin, the gap is stated plainly instead of papered over.

What the name does not claim

The "reviews" modifier in this domain is editorial framing — the position this publisher occupies relative to the literature — not a claim to offer reviews-as-a-service, consultations, ratings, or any healthcare function. There is no clinic, no dispensary, and no prescriber behind this site. Research-grade tesamorelin discussed here is supplied for laboratory study and is not the approved finished drug product; nothing on this site should be read as instruction to obtain or self-administer it. For corrections or source questions, see the contact page.